Welcome to our dedicated page for Cyclacel Phar Pr news (Ticker: CYCCP), a resource for investors and traders seeking the latest updates and insights on Cyclacel Phar Pr stock.
The CYCCP news page on Stock Titan tracks disclosures and press releases related to Cyclacel Pharmaceuticals, Inc.’s 6% Convertible Exchangeable Preferred Stock and the broader corporate developments of the issuer. Company communications describe Cyclacel as a clinical-stage biopharmaceutical company developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with a key focus on the PLK1 inhibitor plogosertib in solid tumors and hematological malignancies.
News items for CYCCP include quarterly financial results, where Cyclacel reports cash resources, research and development spending, and general and administrative expenses, together with commentary on cost reductions, changes in research focus and going concern considerations. These updates often describe the impact of the liquidation of the UK subsidiary Cyclacel Limited, the deconsolidation of that entity’s results, and the company’s decision to concentrate resources on the plogosertib program.
Investors will also find scientific and clinical updates, such as press releases highlighting independent preclinical publications on plogosertib in biliary tract cancer and fibrolamellar hepatocellular carcinoma. These items summarize how PLK1 inhibition and potential biomarkers like BUBR1 or DNAJ–PKAc fusion status may relate to sensitivity to plogosertib, and they provide context for the company’s translational biology strategy.
Another category of CYCCP-linked news covers corporate and capital markets actions, including private placements of Series F Convertible Preferred Stock and associated warrants, amendments to preferred stock and warrant terms, reverse stock splits, and Nasdaq compliance updates. Press releases also detail the Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysian fire safety and protective equipment business, and describe shareholder approvals for share issuances and a corporate name change to Bio Green Med Solution, Inc.
By reviewing this news feed, holders and prospective investors in CYCCP can follow how Cyclacel’s oncology development activities, strategic transactions, financing steps and corporate rebranding are described in its own public statements and SEC-related communications.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its Q2 2025 financial results and significant corporate developments. The company entered a major share exchange agreement with FITTERS Diversified Berhad, where Fitters Parent will exchange 100% of FITTERS Sdn. Bhd. for approximately 19.99% of Cyclacel's common stock, plus $1,000,000 in cash consideration.
Key financial highlights include cash position of $4.3 million as of June 30, 2025, up from $3.2 million in December 2024. The company raised $3 million through Series F Convertible Preferred Stock offering and implemented a 1-for-15 reverse stock split to meet Nasdaq requirements. Q2 2025 saw reduced R&D expenses of $0.1 million (vs $2.0 million in Q2 2024) and lower G&A expenses of $1.2 million (vs $1.6 million in Q2 2024), resulting in a net loss of $1.3 million.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) highlighted promising preclinical data showing the effectiveness of their drug plogosertib in treating biliary tract cancer (BTC). The study, published in Cancer Research, demonstrated that BTC cell lines were sensitive to plogosertib both as a standalone treatment and in combination therapy.
The research revealed that plogosertib works by promoting mitotic checkpoint complex formation, leading to mitotic arrest and cancer cell death. Importantly, the study identified BUBR1 as a potential biomarker for treatment effectiveness, with high BUBR1-expressing cells showing increased sensitivity to the drug. The findings suggest that targeting PLK1 with plogosertib could be an effective strategy for BTC treatment, particularly when combined with ATR inhibitors.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has issued a statement addressing recent unusual stock price movements. The company confirmed that there are no material developments or changes to its operating or financial condition that would explain the significant volume and price fluctuations observed on July 15, 2025.
The biopharmaceutical company emphasized that aside from its previously announced amendment to the Exchange Agreement with FITTERS Diversified Berhad on July 7, 2025, there have been no material adverse changes to its business operations, strategy, or prospects.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced the publication of preclinical data demonstrating the effectiveness of their drug plogosertib in treating fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer affecting young people with no approved treatments.
The study, published in the journal Gut, revealed that FLC cells are highly sensitive to PLK1 inhibition by plogosertib. The research showed that the DNAJ-PKAc fusion oncoprotein, which drives FLC progression, interacts with PLK1 at the centrosome. Notably, plogosertib demonstrated significant reduction in FLC growth while sparing normal liver cells in both in vitro and in vivo models.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has amended its Exchange Agreement with FITTERS Diversified Berhad. The amended agreement includes a new cash consideration of $1 million in addition to the previously agreed stock exchange and extends the final date to September 30, 2025.
Under the Transaction, Cyclacel will acquire all ordinary shares of Fitters Sdn. Bhd., making it a wholly-owned subsidiary, in exchange for Cyclacel common stock representing 19.99% of outstanding shares. The deal requires approval from both companies' stockholders and has received unanimous board approval from all parties involved.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-15 reverse stock split effective July 7, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L876.
Following the split, every 15 shares will automatically convert into one share, with fractional shares being rounded up or down. The total number of outstanding shares will decrease from 23,759,475 to 1,583,965. The reverse split, approved by both the board and stockholders, will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-16 reverse stock split effective May 12, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L884.
Following the split, every 16 shares will automatically convert into one share, with fractional shares being rounded up or down. The pre-split share count of 356,357,531 will be reduced to 22,272,346 post-split. The reverse split was approved by both the board of directors and stockholders, and will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.
FAQ
What is the current stock price of Cyclacel Phar Pr (CYCCP)?
What is the market cap of Cyclacel Phar Pr (CYCCP)?
